Biogen Inc (BIIB) Company Profile & Statistics

Biogen Inc
BIIB
(Nasdaq - US)
Closed
164.84
-0.95 (-0.57%)
in:usd•As of: Nov 14, 2024 15:59 UTC -5
After Market:165.19+0.35 (+0.21%)
Open
164.43
High
175.75
Low
163.60

About Biogen Inc

CEO

Christopher A. Viehbacher

Headquarters

225 binney street

cambridge, ma 02142, united states

Auditor

PricewaterhouseCoopers LLP

Employees

7,570

Share Holders

420

Website

www.biogen.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).

Biogen Inc Statistics

Valuation Measures

Market Capitalization ²	24.02B
Enterprise Value	28.40B
Enterprise Value/EBITDA (ttm)	10.94
Price to Earnings Ratio (ttm)	10.53
Price to Book (mrq)	1.50
Price to Sales (ttm)	2.55
Price to Cash (ytd)	9.13

Profitability

Gross Margin (ttm)	75.59%
Operating Margin (ttm)	24.27%
Profit Margin (ttm)	16.77%
Return on Equity (ttm)	14.98%
Return on Invested Capital (ttm)	7.47%
Return on Assets (ttm)	8.59%

Income Statement

Revenue (ttm)	9.67B
Revenue Per Share (ttm)	66.40
Gross Profit (ttm)	7.31B
EBITDA (ttm)³	2.60B
Net Income Avi to Common (ttm)	1.16B
Diluted EPS (ttm)	11.07

Share Statistics

Beta (5Y Monthly)	-0.06
52-Week Change	-28.21%
S&P500 52-Week Change	32.12%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	145.66M
Dividend Yield	0.00%
Float ⁴	145.49M
% Held by Insiders	0.16%
% Held by Institutions	87.93%

Balance Sheet

Total Cash (mrq)	1.91B
Total Cash Per Share (mrq)	13.11
Total Debt (mrq)	6.29B
Total Debt/Equity (mrq)	38.47%
Current Ratio (mrq)	1.26%
Quick Ratio (mrq)	0.80%
Book Value Per Share (mrq)	112.28

Cash Flow

Operating Cash Flow Per Share (ytd)	14.47
Free Cash Flow (ytd)	2.00B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Biogen Inc

Trade With A Regulated Broker